Skip to main content
Erschienen in: Pituitary 5/2015

01.10.2015

Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study

verfasst von: Chris Yedinak, Nadia Hameed, Marika Gassner, Jessica Brzana, Shirley McCartney, Maria Fleseriu

Erschienen in: Pituitary | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare hypothalamus–pituitary–adrenal (HPA) axis integrity at diagnosis and recovery after transsphenoidal surgery (TSS), in acromegaly patients, compared with tumor size matched non-functioning adenoma (NFA) patients.

Methods

A retrospective 7-year evaluation of acromegaly patients, who underwent TSS with 52 weeks follow-up at a single institution, was undertaken. 50 acromegaly with complete follow-up data at all points and 50 NFA patients were matched for tumor size; HPA axis was similarly assessed pre-operatively and at 6, 12 and 52 weeks post-operatively. Recovery of HPA axis and gender specific prevalence of adrenal insufficiency (AI), were analyzed in both groups. We also studied AI in acromegaly patients requiring medical therapy post-operatively vs those in remission after surgery.

Results

AI remained less prevalent in acromegaly vs NFA (acromegaly, p = 0.01; NFA, p = 0.15) at 52 weeks after surgery, although the prevalence of AI decreased in both groups from baseline by 52 weeks. Additionally, recovery from baseline AI was significantly greater by 52 weeks in acromegaly patients over NFA patients (p = 0.001). Recovery of HPA axis in acromegaly patients remained significant (p = 0.03) despite the need for medical therapy. AI at baseline was proportionately more prevalent in acromegalic males at baseline (p = 0.002) but no gender difference was apparent at 52 weeks (p = 0.35). Conversely, in NFA patients, no gender difference was apparent pre-operatively (p = 0.49), but AI was more prevalent in males at 52 weeks (p = 0.001).

Conclusion

In the longest comparative study to date using a standard assessment modality, HPA axis recovery was more frequent in acromegaly compared to NFA patients, independent of tumor size, cavernous sinus invasion (CSI), and body mass index (BMI). HPA axis integrity must be carefully and periodically monitored in acromegaly patients during short- and long-term follow-up to prevent overtreatment with glucocorticoids.
Literatur
2.
Zurück zum Zitat Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A (2008) Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 93(6):2035–2041CrossRefPubMed Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A (2008) Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 93(6):2035–2041CrossRefPubMed
3.
Zurück zum Zitat Arafah BM (1986) Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 62(6):1173–1179CrossRefPubMed Arafah BM (1986) Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 62(6):1173–1179CrossRefPubMed
4.
Zurück zum Zitat Greenman Y, Tordjman K, Kisch E, Razon N, Ouaknine G, Stern N (1995) Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas. J Clin Endocrinol Metab 80(5):1577–1583PubMed Greenman Y, Tordjman K, Kisch E, Razon N, Ouaknine G, Stern N (1995) Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas. J Clin Endocrinol Metab 80(5):1577–1583PubMed
5.
Zurück zum Zitat Tominaga A, Uozumi T, Arita K, Kurisu K, Yano T, Hirohata T (1995) Anterior pituitary function in patients with nonfunctioning pituitary adenoma: results of longitudinal follow-up. Endocr J 42(3):421–427CrossRefPubMed Tominaga A, Uozumi T, Arita K, Kurisu K, Yano T, Hirohata T (1995) Anterior pituitary function in patients with nonfunctioning pituitary adenoma: results of longitudinal follow-up. Endocr J 42(3):421–427CrossRefPubMed
6.
Zurück zum Zitat Webb SM, Rigla M, Wagner A, Oliver B, Bartumeus F (1999) Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J Clin Endocrinol Metabolism 84(10):3696–3700CrossRef Webb SM, Rigla M, Wagner A, Oliver B, Bartumeus F (1999) Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J Clin Endocrinol Metabolism 84(10):3696–3700CrossRef
7.
Zurück zum Zitat Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10(4):243–248CrossRefPubMed Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10(4):243–248CrossRefPubMed
8.
Zurück zum Zitat Jane JA Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, Marshall JC, Laws ER Jr, Vance ML (2011) Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 96(9):2732–2740CrossRefPubMed Jane JA Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, Marshall JC, Laws ER Jr, Vance ML (2011) Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 96(9):2732–2740CrossRefPubMed
9.
Zurück zum Zitat Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294–302PubMedCentralCrossRefPubMed Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294–302PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA Jr (2013) Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 98(8):3190–3198CrossRefPubMed Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA Jr (2013) Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 98(8):3190–3198CrossRefPubMed
11.
Zurück zum Zitat Burgers AM, Kokshoorn NE, Pereira AM, Roelfsema F, Smit JW, Biermasz NR, Romijn JA (2011) Low incidence of adrenal insufficiency after transsphenoidal surgery in patients with acromegaly: a long-term follow-up study. J Clin Endocrinol Metab 96(7):E1163–E1170CrossRefPubMed Burgers AM, Kokshoorn NE, Pereira AM, Roelfsema F, Smit JW, Biermasz NR, Romijn JA (2011) Low incidence of adrenal insufficiency after transsphenoidal surgery in patients with acromegaly: a long-term follow-up study. J Clin Endocrinol Metab 96(7):E1163–E1170CrossRefPubMed
12.
Zurück zum Zitat Ronchi CL, Ferrante E, Rizzo E, Giavoli C, Verrua E, Bergamaschi S, Lania AG, Beck-Peccoz P, Spada A (2008) Long-term basal and dynamic evaluation of hypothalamic-pituitary-adrenal (HPA) axis in acromegalic patients. Clin Endocrinol 69(4):608–612CrossRef Ronchi CL, Ferrante E, Rizzo E, Giavoli C, Verrua E, Bergamaschi S, Lania AG, Beck-Peccoz P, Spada A (2008) Long-term basal and dynamic evaluation of hypothalamic-pituitary-adrenal (HPA) axis in acromegalic patients. Clin Endocrinol 69(4):608–612CrossRef
13.
Zurück zum Zitat Fleseriu M (2013) The role of combination medical therapy in acromegaly: hope for the nonresponsive patient. Curr Opin Endocrinol Diabetes Obes 20(4):321–329PubMed Fleseriu M (2013) The role of combination medical therapy in acromegaly: hope for the nonresponsive patient. Curr Opin Endocrinol Diabetes Obes 20(4):321–329PubMed
14.
Zurück zum Zitat Fleseriu M, Delashaw JB Jr, Cook DM (2010) Acromegaly: a review of current medical therapy and new drugs on the horizon. Neurosurg Focus 29(4):E15CrossRefPubMed Fleseriu M, Delashaw JB Jr, Cook DM (2010) Acromegaly: a review of current medical therapy and new drugs on the horizon. Neurosurg Focus 29(4):E15CrossRefPubMed
15.
Zurück zum Zitat Fleseriu M (2014) Advances in the pharmacotherapy of patients with acromegaly. Discov Med 18(96):329–338 Fleseriu M (2014) Advances in the pharmacotherapy of patients with acromegaly. Discov Med 18(96):329–338
16.
Zurück zum Zitat Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439–446CrossRefPubMed Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439–446CrossRefPubMed
17.
Zurück zum Zitat Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94(11):4216–4223CrossRefPubMed Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94(11):4216–4223CrossRefPubMed
18.
Zurück zum Zitat Sherlock M, Reulen RC, Aragon-Alonso A, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2014) A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J Clin Endocrinol Metab 99(2):478–485CrossRefPubMed Sherlock M, Reulen RC, Aragon-Alonso A, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2014) A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J Clin Endocrinol Metab 99(2):478–485CrossRefPubMed
19.
Zurück zum Zitat Ben-Shlomo A (2010) Pituitary gland: predictors of acromegaly-associated mortality. Nat Rev Endocrinol 6(2):67–69CrossRefPubMed Ben-Shlomo A (2010) Pituitary gland: predictors of acromegaly-associated mortality. Nat Rev Endocrinol 6(2):67–69CrossRefPubMed
20.
Zurück zum Zitat Sherlock M, Stewart PM (2013) Updates in growth hormone treatment and mortality. Curr Opin Endocrinol Diabetes Obes 20(4):314–320PubMed Sherlock M, Stewart PM (2013) Updates in growth hormone treatment and mortality. Curr Opin Endocrinol Diabetes Obes 20(4):314–320PubMed
21.
Zurück zum Zitat Zueger T, Kirchner P, Herren C, Fischli S, Zwahlen M, Christ E, Stettler C (2012) Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab 97(10):E1938–E1942CrossRefPubMed Zueger T, Kirchner P, Herren C, Fischli S, Zwahlen M, Christ E, Stettler C (2012) Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab 97(10):E1938–E1942CrossRefPubMed
22.
Zurück zum Zitat Fleseriu M, Gassner M, Yedinak C, Chicea L, Delashaw JB Jr, Loriaux DL (2010) Normal hypothalamic-pituitary-adrenal axis by high-dose cosyntropin testing in patients with abnormal response to low-dose cosyntropin stimulation: a retrospective review. Endocr Pract 16(1):64–70CrossRefPubMed Fleseriu M, Gassner M, Yedinak C, Chicea L, Delashaw JB Jr, Loriaux DL (2010) Normal hypothalamic-pituitary-adrenal axis by high-dose cosyntropin testing in patients with abnormal response to low-dose cosyntropin stimulation: a retrospective review. Endocr Pract 16(1):64–70CrossRefPubMed
23.
Zurück zum Zitat Kazlauskaite R, Evans AT, Villabona CV, Abdu TA, Ambrosi B, Atkinson AB, Choi CH, Clayton RN, Courtney CH, Gonc EN, Maghnie M, Rose SR, Soule SG, Tordjman K (2008) Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab 93(11):4245–4253CrossRefPubMed Kazlauskaite R, Evans AT, Villabona CV, Abdu TA, Ambrosi B, Atkinson AB, Choi CH, Clayton RN, Courtney CH, Gonc EN, Maghnie M, Rose SR, Soule SG, Tordjman K (2008) Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab 93(11):4245–4253CrossRefPubMed
24.
Zurück zum Zitat Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol 58(1):86–91CrossRef Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol 58(1):86–91CrossRef
25.
Zurück zum Zitat Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83(10):3419–3426PubMed Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83(10):3419–3426PubMed
26.
Zurück zum Zitat Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR (2000) The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab 85(5):1789–1793PubMed Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR (2000) The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab 85(5):1789–1793PubMed
27.
Zurück zum Zitat Berg C, Meinel T, Lahner H, Mann K, Petersenn S (2010) Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery. Eur J Endocrinol 162(5):853–859CrossRefPubMed Berg C, Meinel T, Lahner H, Mann K, Petersenn S (2010) Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery. Eur J Endocrinol 162(5):853–859CrossRefPubMed
28.
Zurück zum Zitat Marazuela M, Astigarraga B, Vicente A, Estrada J, Cuerda C, Garcia-Uria J, Lucas T (1994) Recovery of visual and endocrine function following transsphenoidal surgery of large nonfunctioning pituitary adenomas. J Endocrinol Investig 17(9):703–707CrossRef Marazuela M, Astigarraga B, Vicente A, Estrada J, Cuerda C, Garcia-Uria J, Lucas T (1994) Recovery of visual and endocrine function following transsphenoidal surgery of large nonfunctioning pituitary adenomas. J Endocrinol Investig 17(9):703–707CrossRef
29.
Zurück zum Zitat Wass JA, Reddy R, Karavitaki N (2011) The postoperative monitoring of nonfunctioning pituitary adenomas. Nat Rev Endocrinol 7(7):431–434CrossRefPubMed Wass JA, Reddy R, Karavitaki N (2011) The postoperative monitoring of nonfunctioning pituitary adenomas. Nat Rev Endocrinol 7(7):431–434CrossRefPubMed
30.
Zurück zum Zitat Caputo C, Sutherland T, Farish S, McNeill P, Ng KW, Inder WJ (2013) Gender differences in presentation and outcome of nonfunctioning pituitary macroadenomas. Clin Endocrinol 78(4):564–570CrossRef Caputo C, Sutherland T, Farish S, McNeill P, Ng KW, Inder WJ (2013) Gender differences in presentation and outcome of nonfunctioning pituitary macroadenomas. Clin Endocrinol 78(4):564–570CrossRef
31.
Zurück zum Zitat Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA (1999) Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol 50(5):561–567CrossRef Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA (1999) Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol 50(5):561–567CrossRef
32.
Zurück zum Zitat Buchfelder M, Schlaffer S (2009) Surgical treatment of pituitary tumours. Best Pract Res Clin Endocrinol Metab 23(5):677–692CrossRefPubMed Buchfelder M, Schlaffer S (2009) Surgical treatment of pituitary tumours. Best Pract Res Clin Endocrinol Metab 23(5):677–692CrossRefPubMed
33.
Zurück zum Zitat Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM (1999) Outcome of surgery for acromegaly–the experience of a dedicated pituitary surgeon. QJM 92(12):741–745CrossRefPubMed Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM (1999) Outcome of surgery for acromegaly–the experience of a dedicated pituitary surgeon. QJM 92(12):741–745CrossRefPubMed
34.
Zurück zum Zitat Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17(6):610–638PubMed Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17(6):610–638PubMed
35.
Zurück zum Zitat Luini A, Lewis D, Guild S, Schofield G, Weight F (1986) Somatostatin, an inhibitor of ACTH secretion, decreases cytosolic free calcium and voltage-dependent calcium current in a pituitary cell line. J Neurosci 6(11):3128–3132PubMed Luini A, Lewis D, Guild S, Schofield G, Weight F (1986) Somatostatin, an inhibitor of ACTH secretion, decreases cytosolic free calcium and voltage-dependent calcium current in a pituitary cell line. J Neurosci 6(11):3128–3132PubMed
36.
Zurück zum Zitat Shimon I (2003) Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 20(3):265–269CrossRefPubMed Shimon I (2003) Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 20(3):265–269CrossRefPubMed
37.
Zurück zum Zitat Mazziotti G, Giustina A (2013) Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 9(5):265–276CrossRefPubMed Mazziotti G, Giustina A (2013) Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 9(5):265–276CrossRefPubMed
38.
Zurück zum Zitat Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19(6):717–797PubMed Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19(6):717–797PubMed
39.
Zurück zum Zitat Agha A, Monson JP (2007) Modulation of glucocorticoid metabolism by the growth hormone–IGF-1 axis. Clin Endocrinol 66(4):459–465 Agha A, Monson JP (2007) Modulation of glucocorticoid metabolism by the growth hormone–IGF-1 axis. Clin Endocrinol 66(4):459–465
40.
Zurück zum Zitat Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF, Stewart PM (1999) Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 84(11):4172–4177PubMed Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF, Stewart PM (1999) Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 84(11):4172–4177PubMed
41.
Zurück zum Zitat Stewart PM, Toogood AA, Tomlinson JW (2001) Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res 56(Suppl.):11–16 Stewart PM, Toogood AA, Tomlinson JW (2001) Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res 56(Suppl.):11–16
Metadaten
Titel
Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study
verfasst von
Chris Yedinak
Nadia Hameed
Marika Gassner
Jessica Brzana
Shirley McCartney
Maria Fleseriu
Publikationsdatum
01.10.2015
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 5/2015
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-015-0643-8

Weitere Artikel der Ausgabe 5/2015

Pituitary 5/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.